Purpose: The aims of this study were as follow: 1) to de scribe the expression status of estrogen receptor-α and -β mRNAs in five gastric carcinoma cell lines; 2) to evaluate in vitro the effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of the cell lines. Materials and Methods: Detection of estrogen receptor-α and estrogen receptor-β mRNA in five human gastric cancer cell lines (AGS, KATO III, MKN28, MKN45 and MKN74) was made by the reverse transcription-polymerase chain reaction system. To evaluate the effect of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell line, the cell lines which expressed both es trogen receptors were chosen and treated with 17β-estradiol and estrogen receptor antagonists (methyl-piperidino-pyrazole and pyrazolo [1,5-a] pyrimidine). Cell proliferation was assessed with the methylthiazol tetrazolium test. Results: Estrogen receptor-α and estrogen receptor-β mRNAs were expressed in three (KATO III, MKN28 and MKN45) and all of the five gastric cancer cell lines, respectively. At higher concentrations, 17β-estradiol inhibited cell growth of MKN28, MKN45 and KATO III cell lines. Neither estrogen receptor-α nor estrogen receptor-β antagonist blocked the anti-proliferative effect of 17β-estradiol. Conclusions: Our results indicate that estrogen receptor-β mRNAs are preferentially expressed in gastric cancers and also imply that hormone therapy rather than estrogen receptor blockers may be a useful strategy for the treatment of estrogen receptor-β positive gastric cancer. Its therapeutic significance in gastric cancer are, however, limited until more evidence of the roles of estrogen receptors in the gastric cancer are accumulated.
Introduction
Estrogens regulate the growth, differentiation, and functioning of diverse target tissues, both within and outside of the reproductive system. 1 Although the stomach is not known as a direct target organ of sex hormones, both epidemiologic and animal studies suggest that gastric cancer may be estrogen-sensitive. A male dominance in the incidence of gastric cancer with a male to female ratio of about 2 : 1 sets up a hypothesis that estrogens may play a protective role against adenocarcinoma of the stomach. 2 The risk of developing gastric cancer was lower among patients with prostate cancer who had been treated with estrogen than in those without such treatment. 3 Studies which have shown that tamoxifen exposure has also been shown to be a risk factor for gastric cancer further support the hypothesis. 4 Reduced risk of gastric cancer in a nationwide cohort study of men with a diagnosis of prostate cancer who had been treated with estrogen were reported. 3 According to the experiment by Furukawa et al., 5 the carcinogenic N-methyl-N0-nitro-N-nitrosoguanidine added to drinking water induced gastric cancer in male rats but not in female, and castrated or estrogentreated male rats had a lower incidence of gastric cancer compared to untreated male rats.
Most of the actions of estrogens are exerted via the estrogen receptor (ER) of target cells, and 2 ER subtypes, ER-α and ER-β, mediate the genomic actions of estrogens. The presence of ER-α and β in gastric adenocarcinoma has been also demonstrated. 5, 6 The discovery of ERs has raised enormous interests in possible role of these receptors in the carcinogenesis, progression and treatment of gastric cancer. 2 To date, however, only limited data regarding the detection of ERs in gastric tumors and cell lines are available, and significance of ER expression and hormone manipulation in gastric cancer is not established.
The aims of this pilot study were: 1) to describe the expression status of ER-α and -β mRNAs in five gastric carcinoma cell lines;
2) to evaluate in vitro the effects of 17β-estradiol and ER antagonists on the proliferation of the cell lines.
Materials and Methods (Fig. 1B) . 
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Discussion
Estrogens regulate the growth, differentiation, and functioning of various target tissues, and their effects are mediated by the receptors, ER-α and ER-β. ER-α and ER-β have distinct cellular distributions; ER-α is predominantly expressed in female sex organs such as the breast, uterus and ovaries, and ER-β is far more widely distributed in the body than is ER-α. 7, 8 The oncologic importance of estrogens and ERs in cancers arising in classic target organs for estrogens such as breast and uterine endometrium have been well described. [9] [10] [11] [12] [13] [14] Estrogens and their receptors also have an important role in the progression of cancers of gastrointestinal tract which has been believed to be nontarget system for estrogens. In contrast to the cancer-promoting role of estrogen in breast and gynecologic cancers, it functions as a suppressor for gastrointestinal cancers. 15 Current use of estrogen therapy is suggested to be associated with a decreased risk of colorectal cancer among peri-or postmenopausal women, 13, 16 and in comparison with tumors with high ER-β expression, tumors negative for ER-β were associated with advanced cancer stages. 17 Most studies on esophageal adenocarcinoma are consistent in suggesting a detrimental effect and prognostic value for ER-β. 7 Contrasting results have been obtained with regard to the expression level of ERs in gastric cancer. Some studies show that only ER-β is expressed in gastric cancer, 18, 19 whereas others reported that the both ERs are expressed. [20] [21] [22] This prompted us to reevaluate ER status and hormonal modulation of cell growth in human gastric cancer.
Cultured gastric cancer cell line is a useful tool to study the effect of hormones in conditions that are independent of neural, hormonal, and blood flow factors. 23 Past studies performed on gastric cancer cell lines showed contrasting actions of estrogens on the cell growth. Diverse effects of estradiol on the growth of six human gastric xenografts in nude mice were found, including one case of stimulation, two of inhibition and three of unchanged condition. 24 Messa et al. 23, 25 showed that 17β-estradiol administration exerts a growth-inhibitory effect on ER-positive cell lines (HGC-27, AGS). On the other hand, Wu et al. 26 found that steroid hormone administration in ER-negative human gastric carcinoma cell line NUGC-3 had a slight stimulatory effect. These studies, however, did not distinguish ER-β from ER-α. The discovery of ER-β, 12 a second ER isoform, has prompted renewed investigation into the mechanism of action of estrogenic molecules. However, the biologic significance of the ERs in gastric cancer still remains to be elucidated.
In the present study, ER-α and ER-β mRNAs were expressed in three (KATO III, MKN28 and MKN45) and all of the five gastric cancer cell lines, respectively. ER-α mRNA was not expressed in AGS and MKN74 cell lines and the ER-α/β-actin ratios were very low in MKN28 and MKN45 (0.28 and 0.04, respectively). Our results indicated that ER-β mRNAs are preferentially expressed in gastric cancers, as Takano et al. 20 reported, and ER-β plays more important role in both physiologic and oncologic processes in gastric tissues than ER-α.
Imbalanced ER-α/ER-β expression, i.e., an increase in ER-α/ ER-β mRNA and protein ratios, is a common feature and could be a critical step of estrogen-dependent tumor progression, and ER-β seems to play a key role in the mitogenic action of estrogen by providing protection against ER-α-induced hyperproliferation. suggested a survival benefit in tamoxifen treated patients with gastric cancer but the sample size was small and patients received chemotherapy. 28 A randomized clinical study by Harrison et al showed that ER-α positive patients survived for a significantly shorter time than untreated controls if they were treated with tamoxifen. ER-α negative patients had a longer survival and tamoxifen did not significantly affect prognosis. 29, 30 On the contrary to these old reports, Kameda et al. 31 recently reported that 17β-estradiol-induced cell proliferation was suppressed by pure anti-estrogen drug, ICI 182, 780 and suggested that the development of clinically available antagonists that can sufficiently block estrogen-induced cell proliferation is promising for management of patients with aggressive diffuse-type gastric cancer. They suggested a possibility that different anti-estrogens used in the above studies may explain the discrepancies in results.
In the present study, MPP and PHTPP were used as ER-α and ER-β antagonists, respectively. MPP is a highly selective ER-α antagonist with 200 fold greater affinity for ER-α versus ER-β, 32 and PHTPP is a potent ER-β antagonist, with negligible activity with ER-α. 33 The present study, however, showed that neither ER-α nor ER-β antagonist had effect on anti-proliferative effect of 17β-estradiol. In our previous study, immunohistochemical staining of ER-α showed no positivity in any of the tissue microarrays of gastric adenocarcinoma tissues, although ER-α was expressed in normal and gastric adenocarcinoma tissues on Western blot analysis. 19 The expression of a particular gene mRNA may not always correspond with the expression of the functional protein. 21 Our present study imply that hormone therapy rather than ER blockers may be a useful strategy for the treatment of gastric cancer in cases of ER-β positive gastric cancer. However, our study has some limitations. Our data do not show clear relationship between the effect of 17β-estradiol and ER-β. 17β-estradiol showed no effect on two ER-β positive cell line. Furthermore, ER antagonists failed to block the effect of 17β-estradiol in this study. The mechanism by which estrogens and their receptors inhibit the growth of cancer cell should be clarified by further studies.
